Attendance from
Biopharma & Big Pharma
65%
Europe's Focal Forum for Manufacturing Excellence, Formulation & Outsourcing
3-4 November 2026
Radisson Blu Hotel, London Heathrow, London, United Kingdom
Attendance from
CDMO
15%
Attendance from
Solution/ Technology & Equipment Providers
10%
Attendance from
Research Institutes
5%
Decision Makers
VP / Global Head / Site Head / Head of CMC / Manufacturing
C-Suite / EVP (CEO, COO, CSO, CTO)
Director / Associate Director
Senior Manager / Manager
Scientist / Engineers
Business Development
By Geography
Day 1 | 3 November 2026 |
|
|
|
|
Biologics Manufacturing Strategy
|
Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
|
| Networking Break | |
|
Optimising CDMO Partnerships and Technical Transfer
Spotlight: ADC Outsourcing Excellence
|
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
|
| Lunch | |
|
Next-Gen Upstream Processing
|
Formulation Supply Chain – From Clinical to Commercial
|
|
Downstream Purification Optimisation
|
|
| Networking Break | |
|
Strategies For Selecting & Managing CDMOs
|
|
|
Industry Roundtables
|
|
| End of Conference Day 1 | |
Day 2 | 4 November 2026 |
|
|
|
|
|
Managing Quality Oversight Across External Manufacturing Networks
|
From Formulation to Device Integration
AI Driven Manufacturing
|
| Networking Break | |
|
AI & Data Analytics for Process Robustness
|
Next-Generation Therapeutics: RNA, Formulation & Process Innovation
|
| Lunch | |
|
Building Future-Ready Biomanufacturing Capacity
Supply Chain Resilience and Logistics
|
Smart Aseptic Fill–Finish
|
|
Panel Discussion - The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
|
|
| Networking Break | |
|
Closing Panel Discussion: Future of European Biomanufacturing
|
|
| End of Conference | |
DAY 1
3 November 2026
08:50
Chairman’s Welcome Address
Dr Uwe Gottschalk
Operating Partner, Keensight Capital, France
09:00
Supply Chain Decision Intelligence – Increasing the Volume & Velocity of Decisions
- Leveraging real-time data analytics to improve visibility across end-to-end biologics supply networks
- Using AI-driven forecasting to accelerate decision-making on demand shifts, capacity, and inventory
- Integrating cross-functional data streams to reduce bottlenecks and improve responsiveness
- Enhancing risk detection and scenario planning to support faster, more confident supply chain decisions
Niveth Richard
Supply Chain Decision Intelligence Lead, GSK, UK
09:25
Architecture Control of Lipid Nanoparticles Enabled by Process Analytics
- Size, Morphology control of lipid nanoparticles
- Automated process development platform enabled by inline DLS measurements
- Preserving lipid nanoparticle architecture from development to manufacturing scale
Solution Provider
Peter Sagmeister
Co-Founder, BIZON Labs, Austria
09:50
Biologics manufacturing Fit for Future - managing more complex molecules and a diverse product range
- Changing from fewer, larger products to smaller
- Besides reliability and quality increase flexibility in the organization
- Improve installations with limited changes for new or non-standard products
- Use AI and mulitavariant analysis to use the data to have the best impact
Dirk Boehm
Site Head DS Penzberg (VP), Roche, Germany
10:15
Accelerate mAb & ADC developability and LNP workflows with Unchained Labs
-
AI-Powered Biologics Characterisation: Leveraging large biophysical datasets to assess protein, antibody and conjugate developability.
- High-Throughput Analytics: Simplifying complex, labour-intensive testing through low-volume biologics analysis and the AI Developability Workcell.
- End-to-End Nanoparticle Development: Supporting nucleic acid payload screening, encapsulation, formulation optimisation and process development.
- Scalable LNP Workflows: Using the Sunny suite to transition seamlessly from early-stage research to GMP-scale production.
- Integrated Analytical Solutions: Ensuring consistency, efficiency and scalability across nanoparticle development workflows
Solution Provider
Andre Mueller
Director of Product Management, Unchained Labs, USA
11:10
Building Faster, Smarter and More Predictable Technology Transfers with Digital Intelligence
-
Building a trusted CMC data foundation as the backbone for faster, more reliable transfers
-
Connecting AI, automation and digital tools across the end-to-end technology-transfer process
-
Translating digital insights into manufacturing readiness, reduced risk and fewer pre-PPQ runs
-
Establishing measurable standards for value tracking, acceleration and continuous improvement
-
Scaling a repeatable approach across products, modalities, sites and partnerships
Filippo Ramondelli
Associate Director - TT & Project Management Lead, Takeda, Italy
11:35
Supporting ADC From IND To The Long Term Commercial Supply: A Step Ahead Against The Challenges Of The Bioconjugates
- Serving the Innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Driving ADC Success with Flexible & High-Quality Solutions from Preclinical to Commercial
- Highlights on the approach to support early stage program through robust development studies.
- Ensuring right first-time-approved regulatory submission to save time and costs.
Solution Provider
Giorgio Salciarini
Head of Sales - Technical Business Development, BSP Pharmaceuticals, Italy
12:00
De-Risking Tech Transfer and Scale-Up of New manufacturing Processes
- Managing successful tech transfer across complex manufacturing processes
- Reducing scale-up risks while maintaining product quality and consistency
- Improving communication and operational alignment between operations and development
- Managing project lifecycle and continuous improvement
Anthony Beaney
Principal Scientist, Lonza Biologics, UK
13:30
Unlocking Biologics Manufacturing Potential: Case Studies in Data Science Applications
- Applying data science to optimize upstream and downstream process performance and reduce variability
- Using advanced analytics to identify root causes of batch deviations and improve yield consistency
- Leveraging predictive models to enhance process control, scale-up success, and tech transfer efficiency
- Demonstrating real-world case studies where data-driven insights improved cost, quality, and time-to-market
Shyam Panjwani
Senior Principal CMC Data Scientist, Bayer, USA
13:55
Glutenase at Scale: Where Process Development Meets Sustainability
- Scalable Process: Developing a cost-efficient, sustainable manufacturing process for TAK-062.
- Process Optimisation: Targeting resource-intensive steps through innovative technologies.
- Key Improvements: Antibiotic-free fermentation, raw material optimisation, and waste reduction.
- Scale-Up: Integrating yield enhancement and process intensification for commercial production.
Michael Palige
Process Development & CMC Lead, Takeda, Austria
14:20
Bispecific Purification: Double Trouble or Twice as Nice?
- Tackling complex product-related impurities in bispecific purification
- Impact of molecular design, clone selection and analytics on manufacturability
- Developing robust, scalable purification strategies for next-generation bispecifics
- Industrial case studies and key lessons learned
Gavin Wild
Head of Early Process Sciences, UCB, UK
15:00
Partnering for Success: Integrating Internal Expertise with External Manufacturing Capabilities
- CDMO selection process, relationship management
- An example of what can be achieved when both parties are aligned on a shared vision.
Franz Schnetzinger
VP / Head PAD & QC, AAVantgarde Bio, UK
15:25
Managing CDMO Partnerships Across Formulation & Clinical Trial Supply Networks
- Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
- Establishing governance models that drive performance, transparency, and long-term collaboration.
- Managing supply chain risks, capacity constraints, and business continuity across external networks.
- Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon
Chief Operating Officer, StablePharma, UK
15:50
Choosing the Right Outsourcing Partner: From Payload to Fill-Finish
- Strategic partner selection for long-term external manufacturing success
- Building strong governance frameworks across global CDMO partnerships
- Strengthening supply resilience and managing operational risk
- Driving performance oversight from development through commercial supply
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:05
Roundtable Discussion
AI in Supply Chain - Are they dependable for decisions?
Scaling Biologics Manufacturing for Future Demand
Maximising Drug Product Manufacturing
Securing Biomanufacturing Supply Chains: Innovative Approaches to Accessing Critical Materials and Consumables (LMICs approach)
The Outsourcing Paradox: Preserving bandwidth without losing scientific expertise and strategic control.
Building High-Trust Sponsor-CDMO Relationships
Formulation as a Commercial Differentiator
DAY 2
4 November 2026
08:50
Chairman’s Welcome Address
Dr Uwe Gottschalk
Operating Partner, Keensight Capital, France
09:00
Building Robust Quality Governance Across Global CDMO Networks
- Establishing effective quality governance frameworks across global CDMO networks
- Strengthening sponsor–CDMO collaboration through clear accountability, communication, and oversight
- Implementing risk-based approaches to supplier management, audits, and quality performance monitoring
- Maintaining inspection readiness and consistent GMP compliance across outsourced manufacturing operations
Marcelo Castro
Senior Director, Global Biopharma External Supply Operations Quality, Pfizer, Ireland
09:25
Enhancing Visibility and Control in External Manufacturing Quality Systems
- Strengthening quality oversight across complex external manufacturing networks
- Improving real-time visibility and risk management within supplier quality systems
- Aligning sponsor–CDMO quality expectations and governance frameworks
- Leveraging digital tools and data analytics to enhance compliance and operational control
Cathal Gallagher
Senior Director-Head of Quality, External Operations EU, Takeda, Ireland
09:50
Speed to Clinic: Tech Transfer and Phase I Manufacturing in Under 6 Months
Solution Provider
Dr Ashwinkumar V Meru
Head of Global Business Development, Kemwell, India
10:15
Strengthening Quality Oversight Across External Manufacturing Networks
- Standardising GMP and quality systems across CDMO partners for consistent compliance
- Using digital QMS tools for real-time deviation tracking and faster resolution
- Strengthening risk-based audits and supplier qualification across sites
- Driving continuous improvement through CAPA and shared quality KPIs
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director, Almirall, Spain
11:10
From Data Rich To Decision Intelligent
- Establishing effective governance frameworks for AI and data across manufacturing and supply chain functions
- Aligning AI and data strategies with business priorities, operational needs and measurable outcomes
- Balancing data quality, accessibility, security and compliance to enable trusted AI adoption
- Moving from individual AI use cases to scalable, cross-functional digital transformation and value creation
Syed Saqib Naqvi
Senior Manager, Digital Excellence, Amicus Therapeutics, UK
11:35
Single Cell Analysis for Enhanced Characterisation
- Leveraging single-cell analysis for deeper product and process characterisation
- Identifying cell-to-cell variability and critical subpopulations
- Linking cellular attributes to productivity and product quality
- Supporting better clone selection and process optimisation
Dr Aurelien Bunga
Senior Scientist, Rinri Therapeutics, UK
12:00
Beyond the Straight Line: Kinetic Modelling for Faster, Defensible Stability Decisions
- How advanced kinetic modelling (AKM) predicts long-term stability and shelf life from accelerated and stress data - reducing the real-time data needed to support a claim from years to months
- Applying one modelling framework across the decisions biomanufacturers actually face: shelf-life determination, temperature-excursion assessment, and internal release limit setting
- Quantifying uncertainty explicitly through prediction bands, rather than assuming it - producing outputs that stand up to regulatory scrutiny
- Why AKM aligns with the direction of the evolving ICH Q1 guidance on model-informed stability strategies.
Dr Warren Roche
Senior Biostatistician Expert, Argenx, Belgium
13:30
From Design to Manufacture: Developing CARKey, a New Generation of Programmable CAR-T Therapy
- Programmable CAR-T design for greater precision and flexibility
- Translating CARKey from design to scalable manufacture
- Optimising CMC, quality and process consistency
- Advancing next-generation CAR-T towards clinical application
Dr John Bridgeman
Chief Scientific Officer, ImmunoKey, UK
13:55
Vaccine manufacturing networks in Low- and Middle-Income Countries
- Strengthening regional vaccine manufacturing capacity and supply resilience in LMICs
- Building sustainable technology transfer and local manufacturing partnerships
- Overcoming infrastructure, workforce, and regulatory challenges across emerging markets
- Enhancing equitable access through scalable and future-ready vaccine manufacturing networks
Vishal Mukund Sonje
Senior Vaccine Manufacturing Lead, CEPI, UK
14:15
CEPI: An Input Materials Supply Organization for African Vaccine Input Material A Supply Consortium Model: Scope, Governance and Investment
- Aggregating demand for critical vaccine input materials and consumables
- Defining the scope of an African supply consortium model
- Establishing governance structures and stakeholder responsibilities
- Exploring investment needs and long-term sustainability
Valerie Chambard-Benalleg
Manufacturing Supply Chain Lead, CEPI, UK
14:55
Panel Discussion
The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
- Resilience in an Increasingly Unpredictable World
- Data, AI & Digitalisation – Creating a More Intelligent Supply Chain
- From Development to Launch – Building Supply Readiness Earlier
- Building the Future Supply Chain – Scalability, Sustainability & Patient Access
Moderator
Dr Christopher van der Walle
Head of Formulation Science, MHRA, UK
Panellists
Brendan Noone
Senior Director, Global Supply Chain & Strategy, AstraZeneca, Ireland
Shyam Panjwani
Senior Principal CMC Data Scientist, Bayer, USA
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland
Kellen LaVigne
Director, Supply Chain & Logistics, Aurion Biotech, USA
Kristin Grande
Senior Manager, Technical Marketing - Life Sciences, Greenfield Global, USA
15:40
Panel Discussion
The Future of European Biomanufacturing: Capabilities, Competitiveness and Innovation
- Biomanufacturing Beyond 2030: Future priorities and preparedness gaps
- Europe’s Competitive Edge: Attracting development and manufacturing investment
- Strategic Partnerships: Enabling scale-up while retaining critical in-house expertise
- AI in Biomanufacturing: Opportunities, risks and implementation readiness
Moderator
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
Panellists
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director, Almirall, Spain
Syed Saqib Naqvi
Senior Manager, Digital Excellence, Amicus Therapeutics, UK
Michael Palige
Process Development & CMC Lead, Takeda, Austria
DAY 1
3 November 2026
08:50
Chairman’s Welcome Address
Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK
09:00
Advanced Formulation Strategies for Complex Biologics: mAbs, Bispecifics & ADCs
- How dripping can impact filling process control
- Reported approaches to avoid dripping in a filling process
- Droplet elongation rate as an indicator of solution propensity for dripping
- Impact of surfactants on solution propensity for dripping at the nozzle tip end
Sébastien Dasnoy
Principal Scientist, Injectable Formulation Development, UCB, Belgium
09:25
Crack the Protein Formulation Code with Aunty
- Protein formulation labs face challenges every day: more samples to test, increasingly complex candidates, and shorter timelines.
- Optimizing stability, manufacturability, and developability requires extensive excipient screening across multiple parameters—all in less time than ever before.
- This talk shows how you can use Aunty to speed up formulation studies from weeks to days using high-throughput, multi-attribute characterization in a 96-well SBS-format quartz plate.
- By combining full-spectrum DSF, SLS, and DLS in a single experiment, you can gather all the melting and aggregation data necessary to make faster, more informed decisions while improving efficiency.
- Automation-ready workflows keep grinding out results long after you’ve called it a day.
- We’ll review a DoE-based excipient screen of three antibodies and an enzyme that identified major stability drivers in a single experiment.
- We’ll also peek into colloidal parameters kD* and B22*, as well as freeze/thaw performance to provide a more complete picture of formulation behavior.
Solution Provider
Andre Mueller
Director of Product Management, Unchained Labs, USA
09:50
From Bioprocess to Formulation: Building Robust and Scalable Strategies for Complex Biologics
- Bridging upstream and downstream bioprocessing with formulation development to ensure product quality and stability.
- Addressing aggregation, viscosity, and stability challenges in complex biologics.
- Optimising process robustness, scalability, and manufacturability from clinical to commercial production.
- Integrating process development, formulation, and CMC strategies to accelerate commercial readiness.
Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK
10:15
Cracking Long-Acting Injectables Translation: Lessons from Small Molecules, Implications for Biologics
- Early PK and biocompatibility data for small‑molecule LAIs often fail to predict clinical outcomes, creating a persistent predictability gap.
- The injection site acts as a complex, dynamic system, where depot behavior, tissue response, and absorption are tightly linked.
- Traditional approaches (e.g., IVIVC) are insufficiently predictive, requiring a shift to mechanistic, model‑informed translation.
- Success depends on integrated CMC–PK–clinical strategies that reduce uncertainty early through coordinated design.
- These learnings are relevant to high concentration /complex biologics, where greater molecular complexity further tightens the link between formulation, delivery, and clinical performance.
Marieta Duvnjak
Head Science & Operations in Analytical Research and Development, Novartis, India
11:10
The CMC Leader Driving Vaccines from Development to Real-World Supply
- Why scientific innovation alone is not enough to ensure successful vaccine or biologics commercialization
- Identifying future CMC challenges before they become development bottlenecks
- Designing products for manufacturability, affordability and sustainable global supply
- The role of strategic CMC leadership in driving vaccines from development to real-world supply
Christine Hägglund
VP CMC Development, Scandinavian Biopharma, Sweden
11:35
Workforce Value-at-Risk: Quantifying Talent Risk Across Biopharma Development and Manufacturing
- Identifying critical workforce gaps and talent shortages across biopharma R&D, process development, and manufacturing.
- Quantifying the impact of workforce risks on productivity, operational efficiency, and manufacturing continuity.
- Developing data-driven strategies to assess skills gaps, workforce readiness, and future talent requirements.
- Building resilient talent pipelines through strategic workforce planning, upskilling, and cross-functional collaboration.
Dr Jason Beckwith
SVP Talent Science & Thought Leadership, BioTalent, UK
12:00
Advancing Cancer Immunotherapies from Discovery to Clinical Development: Aligning Innovation, Formulation, and Patient Impact
- Avancing an active immunotherapy for melanoma (iSCIB1+) from early- to late-phase clinical development
- Aligning formulation, CMC, and manufacturing strategies to support clinical progression
- Leveraging translational insights to establish a robust potency assurance strategy
- Harnessing the advantages of DNA plasmid formulations to maximise patient outcomes
Callum Scott
Senior Vice President, Development, Scancell, UK
13:30
Strengthening Cold Chain and Distribution Strategies for Complex Biologics and Advanced Therapies
- Ensuring end-to-end cold chain integrity for biologics and advanced therapies through robust temperature monitoring and control systems
- Mitigating distribution risks for temperature-sensitive products via real-time tracking, data visibility, and contingency planning
- Optimizing global logistics networks to support timely, compliant, and scalable delivery of complex therapies
- Strengthening collaboration across supply chain stakeholders to maintain product quality from manufacturing to patient delivery
Kellen LaVigne
Director, Supply Chain & Logistics, Aurion Biotech, USA
13:55
Implementing an Innovative Automated Tool to Speed Up Quality Assessments of Clinical and Commercial Drug Product Excursions Globally
- Managing Excursions to Protect Quality and Supply
- Automating Quality Impact Assessments
- Turning Stability Data into Decision Support
- Enabling Consistent Global Implementation
- Reducing Assessment Time by Approximately 50%
Paul de Goede
Principal Scientist Formulation Development, Johnson & Johnson Innovative Medicine, Netherlands
14:20
Bispecific Purification: Double Trouble or Twice as Nice?
- Tackling complex product-related impurities in bispecific purification
- Impact of molecular design, clone selection and analytics on manufacturability
- Developing robust, scalable purification strategies for next-generation bispecifics
- Industrial case studies and key lessons learned
Gavin Wild
Head of Early Process Sciences, UCB, UK
15:00
Partnering for Success: Integrating Internal Expertise with External Manufacturing Capabilities
- CDMO selection process, relationship management
- An example of what can be achieved when both parties are aligned on a shared vision.
Franz Schnetzinger
VP / Head PAD & QC, AAVantgarde Bio, UK
15:25
Managing CDMO Partnerships Across Formulation & Supply Networks (TBC)
- Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
- Establishing governance models that drive performance, transparency, and long-term collaboration.
- Managing supply chain risks, capacity constraints, and business continuity across external networks.
- Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon
Chief Operating Officer, StablePharma, UK
15:50
Choosing the Right Outsourcing Partner: From Payload to Fill-Finish
- Evaluating CDMO capabilities across the full manufacturing workflow
- Strengthening collaboration and oversight across multi-partner supply chains
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:05
Roundtable Discussion
AI in Supply Chain - Are they dependable for decisions?
Scaling Biologics Manufacturing for Future Demand
Maximising Drug Product Manufacturing
Securing Biomanufacturing Supply Chains: Innovative Approaches to Accessing Critical Materials and Consumables (LMICs approach)
The Outsourcing Paradox: Preserving Bandwidth Without Losing Scientific Expertise and Strategic Control
Building High-Trust Sponsor-CDMO Relationships
Formulation as a Commercial Differentiator
DAY 2
4 November 2026
08:50
Chairman’s Welcome Address
Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director), Biogen, Switzerland
09:00
Bridging Formulation, Manufacturing, and Process Development in Advanced Cell Therapies
- Integrating formulation, process development, and manufacturing to ensure consistent quality in advanced cell therapies
- Overcoming scale-up and variability challenges while maintaining cell viability and functional potency
- Developing closed, automated, and scalable processes to enable robust and reproducible cell therapy production
- Aligning cross-functional teams early to streamline tech transfer
Hollie Bartley
Director, Process Development, Resolution Therapeutics, UK
09:25
Nebulized IgG: A Combination Product Odyssey
- Phase appropriate solutions
- Innovation: Balancing development speed with program risk
- Combination product mind set: The whole is greater than the parts
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland
09:50
CMC at the Board Table: Connecting Technical Development with Biotech Strategy
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
10:15
A Digital Future for CMC: Modelling and AI
- Digital innovation in the development and manufacture of medicines
- Models in pharmaceutical development and manufacturing
- Evolution of the regulatory framework for model-based controls
- AI in CMC development and manufacture
- Overcoming barriers to implementation and organisational readiness
- Lessons learned from integrating emerging technologies into development and manufacturing
Tejash Shah
Senior Director, Biopharm CMC Regulatory Affairs, GSK, UK
11:10
The Controlled Temperature Chain and Lyophilised RNA Vaccines
- The motivation for producing lyophilised RNA vaccines
- Lipid nanoparticle formulations of mRNA and saRNA that are suitable for freeze-drying
- Parameters used to identify the formulation space and process analytical technology
- Physico-chemical characterisation and bioassay
- Early stability study read-outs.
Dr Christopher van der Walle
Head of Formulation Science, MHRA, UK
11:35
Turning Junk into Gems: Long Non-Coding RNAs Unlock New Therapeutic Horizons?
- Overview of the non-coding field
- Non-coding elements as novel pharmacological targets
- Developing a technological pipeline for identificaiton and validation of non-coding pharmacological targets
- RNA therapeutics targeting non-coding elements
Alessandro Bonetti
Director, AstraZeneca, UK
12:00
New Strategies for Oral Delivery of Biologics
- Overcoming gastrointestinal barriers, enzymatic degradation, and poor absorption to improve oral bioavailability of biologics.
- Exploring innovative formulation approaches, including nanoparticles, permeation enhancers, and protective delivery systems.
- Advancing targeted intestinal delivery and absorption technologies to improve therapeutic efficacy and patient convenience.
- Addressing formulation stability, scalability, and clinical translation challenges in developing commercially viable oral biologics.
Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery, King’s College London, UK
13:30
From Tech Transfer to Commercial Supply: Ensuring Quality in Fill–Finish Operations
- Ensuring seamless technology transfer from process development to commercial fill–finish manufacturing.
- Strengthening aseptic processing, contamination control, and sterility assurance to maintain product quality.
- Implementing robust process validation, quality control, and regulatory compliance strategies for commercial readiness.
- Optimising fill–finish operations through automation, risk management, and continuous process improvement to ensure reliable commercial supply.
Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director), Biogen, Switzerland
13:55
From tech transfer to commercial supply, Digitalisation of the formulation, MSAT leadership in vaccines formulation fill and finish
- Driving seamless technology transfer from vaccine formulation development to commercial fill–finish manufacturing.
- Leveraging digitalisation, automation, and real-time process monitoring to enhance formulation and manufacturing efficiency.
- Strengthening MSAT leadership in process optimisation, technology transfer, scale-up, and cross-functional collaboration.
- Ensuring product quality, sterility assurance, and regulatory compliance throughout vaccine formulation and commercial fill–finish operations.
Laurent Marcellin
Head of MSAT Vaccines, Takeda, Switzerland
14:15
Beyond OEE: Integrating Asset Excellence, Automation and Contamination Control in Pre-Filled Syringe Manufacturing
- Enhancing asset reliability and operational efficiency beyond traditional OEE metrics.
- Leveraging automation and real-time monitoring to optimise manufacturing performance.
- Strengthening contamination control and sterility assurance in aseptic operations.
- Integrating predictive maintenance and digital technologies to improve quality and scalability.
Tarik Cheema
Asset Excellence Lead Pre-Filled Syringes, Roche, Switzerland
14:55
Panel Discussion
The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
- Resilience in an Increasingly Unpredictable World
- Data, AI & Digitalisation – Creating a More Intelligent Supply Chain
- From Development to Launch – Building Supply Readiness Earlier
- Building the Future Supply Chain – Scalability, Sustainability & Patient Access
Moderator
Dr Christopher van der Walle
Head of Formulation Science, MHRA, UK
Panellists
Christian Zimmer
Executive Director, Head SUT & ADC Drug Substance Manufacturing, Roche, Switzerland
Shyam Panjwani
Senior Principal CMC Data Scientist, Bayer, USA
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland
Kellen LaVigne
Director, Supply Chain & Logistics, Aurion Biotech, USA
Kristin Grande
Senior Manager, Technical Marketing - Life Sciences, Greenfield Global, USA
15:40
Panel Discussion
The Future of European Biomanufacturing: Capabilities, Competitiveness and Innovation
- Biomanufacturing Beyond 2030: Future priorities and preparedness gaps
- Europe’s Competitive Edge: Attracting development and manufacturing investment
- Strategic Partnerships: Enabling scale-up while retaining critical in-house expertise
- AI in Biomanufacturing: Opportunities, risks and implementation readiness
Moderator
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
Panellists
Syed Saqib Naqvi
Senior Manager, Digital Excellence, Amicus Therapeutics, UK
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director, Almirall, Spain
Michael Palige
Process Development & CMC Lead, Takeda, Austria
CHAIRMAN
Dr Uwe Gottschalk
Operating Partner
Keensight Capital
France
Dr Christopher van der Walle
Head of Formulation Science
MHRA
UK
BIG PHARMA
Filippo Ramondelli
Associate Director - TT & Project Management Lead
Takeda
Italy
BIG PHARMA
Niveth Richard
Supply Chain Decision Intelligence Lead
GSK
UK
BIG PHARMA
Marcelo Castro
Senior Director, Global Biopharma External Supply Operations Quality
Pfizer
Ireland
BIG PHARMA
Paul de Goede
Principal Scientist Formulation Development
Johnson & Johnson Innovative Medicine
Netherlands
BIG PHARMA
Shyam Panjwani
Senior Principal CMC Data Scientist
Bayer
USA
BIG PHARMA
Tarik Cheema
Asset Excellence Lead Pre-Filled Syringes
Roche
Switzerland
BIG PHARMA
Marieta Duvnjak
Head Science & Operations in Analytical Research and Development
Novartis
India
BIG PHARMA
Tejash Shah
Senior Director, Biopharm CMC Regulatory Affairs
GSK
UK
BIG PHARMA
Dirk Boehm
Site Head DS Penzberg (VP)
Roche
Germany
BIG PHARMA
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule
CSL
Switzerland
BIG PHARMA
CHAIRMAN
Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director)
Biogen
Switzerland
BIG PHARMA
Laurent Marcellin
Head of MSAT Vaccines
Takeda
Switzerland
BIG PHARMA
Alessandro Bonetti
Director
AstraZeneca
UK
BIG PHARMA
Brendan Noone
Senior Director, Global Supply Chain & Strategy
AstraZeneca
Ireland
BIG PHARMA
Cathal Gallagher
Senior Director-Head of Quality, External Operations EU
Takeda
Ireland
%20Kuforiji.png)
BIG PHARMA
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA)
MSD
Switzerland
Sébastien Dasnoy
Principal Scientist, Injectable Formulation Development
UCB
Belgium
Gavin Wild
Head of Early Process Sciences
UCB
UK
Dr John Bridgeman
Chief Scientific Officer
ImmunoKey
UK
Hollie Bartley
Director, Process Development
Resolution Therapeutics
UK
Kellen LaVigne
Director, Supply Chain & Logistics
Aurion Biotech
USA
Christine Hägglund
VP CMC Development
Scandinavian Biopharma
Sweden
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director
Almirall
Spain
Alexander Hempel
Director Manufacturing
Avethera
Germany
Dr Aurelien Bunga
Senior Scientist
Rinri Therapeutics
UK
Marco Carfagna
Head of Formulation Development & Drug Product Labs
Formycon
Germany
Vishal Mukund Sonje
Senior Vaccine Manufacturing Lead
CEPI
UK
Dr Warren Roche
Senior Biostatistician Expert
Argenx
Belgium
Dr Jason Beckwith
SVP Talent Science & Thought Leadership
BioTalent
UK
Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK
Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery
King’s College London
UK
Callum Scott
Senior Vice President, Development
Scancell
UK
Anthony Beaney
Principal Scientist
Lonza Biologics
UK
Andre Mueller
Director of Product Management
Unchained Labs
USA
Valerie Chambard-Benalleg
Manufacturing Supply Chain Lead
CEPI
UK
Julia Hinteramskogler
Head of Technical Development
Elaris
Austria
Franz Schnetzinger
VP / Head PAD & QC
AAVantgarde Bio
UK
Karen O'Hanlon
Chief Operating Officer
StablePharma
UK
Dr Ashwinkumar V Meru
Head of Global Business Development
Kemwell
India
BIG PHARMA
Michael Palige
Process Development & CMC Lead
Takeda
Austria
Syed Saqib Naqvi
Senior Manager, Digital Excellence
Amicus Therapeutics
UK
Giorgio Salciarini
Head of Sales - Technical Business Development
BSP Pharmaceuticals
Italy
Kristin Grande
Senior Manager, Technical Marketing - Life Sciences
Greenfield Global
USA
Peter Sagmeister
Co-Founder
BIZON Labs
Austria
GOLD
BRONZE
EXHIBITION & NETWORKING
ASSOCIATE
Thought Leadership Speaking
Panel Participation
Solution Showcases
Engagement and Visibility Opportunities
Branding and Digital Visibility
Exclusive Networking
Dr Heiner Apeler
VP Head of Biologics Development
Bayer
Germany
The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.
John Bridgeman
CSO
Immunokey
UK
Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
Switzerland
Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!
Dr Andrew Kelly
Director, Manufacturing Technology
BMS
Ireland
Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
Switzerland
A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.
Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK
Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
Spain
Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
Switzerland
I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.
Terry Gray
Field Marketing Manager
Merck
I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.
Warren Roche
Senior Statistical Expert
Sanofi
Ireland
Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
Ireland
Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.
I hope we have opportunity to connect again in the future.
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
Ireland
Well done on a very informative and successful event.
Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK
Travel Options
By London Underground
From Heathrow Airport
Taxi or Ride-Hailing
By Car
From Other UK Cities
Accommodation Options
Explore recommended hotels near the venue.
Exclusive delegate hotel rate
Please note: the conference registration fee does not include hotel accommodation or travel expenses.
IMAPAC has secured an exclusive discounted room rate for conference delegates. Use one of the booking options below and quote the conference block code where applicable.
Please complete your booking by 03 October 2026 to secure the discounted conference rate. Bookings made after the cut-off date are subject to hotel availability and may be charged at the prevailing room rate.
Standard Double Room
- Single occupancy£129.00
- Double occupancy£139.00
Rates include full breakfast.
Venue Hotel
Special Rate
Radisson Blu Hotel, London Heathrow
140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event
To book a room at this hotel, please click the button below
London Heathrow Mariott Hotel
Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue
To book a room at this hotel, please click the button below
Ibis Style London Heathrow Airport
272 Bath Rd, London UB3 5AY
8 minute walk from venue
To book a room at this hotel, please click the button below
Premier Inn London Heathrow
15 Bath Rd, London TW6 2AB
5 minute drive from venue
To book a room at this hotel, please click the button below
Please find the booth allocation in the table below.
3
Briggs of Burton
4
Alfa Laval
7a
MabPlex
7b
Greenfield Global
8
BSP Pharmaceuticals
11
QuickSTAT
14
AsTec Chemicals
17
Unchained Labs
18
Kemwell Biopharma
19
Inprocess LSP
